Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday...
11 March 2019 - 11:03PM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, today announced that it
will release fourth quarter and year end 2018 financial results
after market close on Monday, March 18, 2019. Further,
Catalyst management will host an investment-community conference
call at 8:30 a.m. ET on Tuesday, March 19, 2019 to
discuss the financial results and to provide a corporate update.
Investors who wish to participate in the
conference call may do so by dialing (877) 407-8912 for domestic
and Canadian callers or (201) 689-8059 for international callers.
Those interested in listening to the conference call live via the
internet may do so by visiting the Investors page of the company's
website at www.catalystpharma.com and clicking on the
webcast link on the Investors home page.
A webcast replay will be available on the
Catalyst website for 30 days following the call by visiting the
Investor page of the company's website
at www.catalystpharma.com.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical
company focused on developing and commercializing innovative
therapies for people with rare debilitating, chronic neuromuscular
and neurological diseases, including Lambert-Eaton myasthenic
syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK
antibody positive myasthenia gravis (MuSK-MG) and spinal muscular
atrophy (SMA) Type 3. Catalyst's new drug application for
Firdapse® (amifampridine) 10 mg tablets for the treatment of adults
with LEMS was recently approved by the U.S. Food & Drug
Administration ("FDA"), and Firdapse is now commercially
available in the United States. Prior to its approval,
Firdapse for LEMS had received breakthrough therapy designation and
orphan drug designation from the FDA.
Firdapse is currently being evaluated in
clinical trials for the treatment of CMS, MuSK-MG and SMA Type 3
and has received Orphan Drug Designation from the FDA for
CMS and myasthenia gravis. Firdapse (amifampridine) 10 mg tablets
is the first and only approved drug in Europe for the
symptomatic treatment in adults with LEMS.
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including (i) whether Catalyst will be
successful in commercializing Firdapse (ii) whether, even if
Catalyst is successful in commercializing Firdapse, Catalyst will
become profitable, (iii) whether Firdapse will ever be approved for
the treatment of CMS, MuSK-MG, SMA Type 3, or any other disease,
and (iv) those other factors described in Catalyst's Annual Report
on Form 10-K for the fiscal year 2017 and its other filings with
the U.S. Securities and Exchange Commission (SEC), could adversely
affect Catalyst. Copies of Catalyst's filings with the SEC are
available from the SEC, may be found on Catalyst's website, or may
be obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Investor Contact
Brian Korb
Solebury Trout
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2024 to May 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From May 2023 to May 2024